β2肾上腺素能受体基因多态性与冠状动脉粥样硬化性心脏病相关性

摘要

目的 探讨β2肾上腺素能受体基因多态性与冠状动脉粥样硬化性心脏病间的相关性,为临床疾病防治提供参考.方法 选取温岭市第一人民医院200例经冠状动脉造影证实为冠状动脉粥样硬化性心脏病患者的临床资料,并纳入研究组,并选取同期入院健康且无冠状动脉粥样硬化性心脏病者200例为对照组.检测2组β2肾上腺素能受体基因多态性,并统计各基因频率.结果 β2肾上腺素能受体基因多态性的基因频数符合Hardy-Weinberg平衡,差异无统计学意义;按照显性遗传模式分析提示,研究组A等位基因型(AA+AG)频率46.0%较对照组58.0%低,且差异具有统计学意义,χ2=5.76,P=0.01;研究组AG基因型频率14.0%明显低于对照组26.0%,χ2=26.20,P=0.00;研究组GG基因型频率54.0%明显高于对照组42.0%,χ2=5.76,P=0.01;研究组G基因频率62.0%与对照组56.0%相比差异无统计学意义;A基因频率38.0%与对照组44.0%相比差异无统计学意义;研究组AA基因频率30.0%与对照组32.0%相比差异无统计学意义.结论 β2肾上腺素能受体基因A/G多态性与冠状动脉粥样硬化性心脏病临床发病存在紧密联系,且A等位基因可能为冠状动脉粥样硬化性心脏病患者保护因素.%Objective To investigate the association between β2-adrenergic receptor gene polymorphism and coronary atherosclerotic heart disease, and to provide reference for clinical disease prevention and treatment.MethodsThe clinical data of 200 patients with coronary atherosclerotic heart disease confirmed by coronary angiography were selected and included in the study group, and 200 healthy subjects without coronary atherosclerotic heart disease group.The polymorphism of β2 adrenergic receptor gene was detected and the frequency of each gene was analyzed.ResultsThe genotype frequencies of β2-adrenergic receptor gene were in accordance with Hardy-Weinberg equilibrium, the difference was not statistically significant.According to dominant genetic model, the frequency of AA+AG was 46.0% vs 58.0% lower than that of the control group, and had statistical significance, The genotype frequency of GG genotype in study group was significantly lower than that in control group 14.0% vs 26.0%, χ2=26.20, P=0.00.The frequency of GG genotype in study group was significantly higher than that in control group 54.0% vs 42.0%, χ2=5.76, P=0.01.The frequency of A gene was 38.0% compared with 44.0% in control group, χ2=1.48, P=0.22;the frequency of AA gene in study group was 30.0%, and the frequency of gene A was 38.0%, compared with 56.0% Compared with 32.0% in the control group, χ2=0.18, P=0.66.ConclusionThe A/G polymorphism of β2-adrenergic receptor gene is closely related to the clinical pathogenesis of coronary atherosclerotic heart disease, and the A allele may be a protective factor in patients with coronary atherosclerotic heart disease.